A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment

Sydney C Yuen; Adaeze Q Amaefule; Hannah H Kim; Breanna-Verissa Owoo; Emily F Gorman; T Joseph Mattingly 2nd

doi:10.1007/s41669-021-00298-z

A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment

Pharmacoecon Open. 2022 Jan;6(1):9-19. doi: 10.1007/s41669-021-00298-z. Epub 2021 Aug 24.

Authors

Sydney C Yuen¹, Adaeze Q Amaefule¹, Hannah H Kim¹, Breanna-Verissa Owoo¹, Emily F Gorman², T Joseph Mattingly 2nd³

Affiliations

¹ University of Maryland School of Pharmacy, 220 Arch Street, 12th Floor, Baltimore, MD, 21201, USA.
² Health Sciences and Human Services Library, University of Maryland, Baltimore, MD, USA.
³ University of Maryland School of Pharmacy, 220 Arch Street, 12th Floor, Baltimore, MD, 21201, USA. jmattingly@rx.umaryland.edu.

Abstract

Background: Hepatocellular carcinoma (HCC) is associated with significant financial burden for patients and payers. The objective of this study was to review economic models to identify, evaluate, and compare cost-effectiveness estimates for HCC treatments.

Methods: A systematic search of the PubMed, Embase, and Cochrane Library databases to identify economic evaluations was performed and studies that modeled treatments for HCC reporting costs and cost effectiveness were included. Risk of bias was assessed qualitatively, considering costing approach, reported study perspective, and funding received. Intervention costs were adjusted to 2021 US dollars for comparison. For studies reporting quality-adjusted life-years (QALYs), we conducted analyses stratified by comparison type to assess cost effectiveness at the time of the analysis.

Results: A total of 27 studies were included. Non-curative versus non-curative therapy comparisons were used in 20 (74.1%) studies, curative versus curative comparisons were used in 5 (18.5%) studies, and curative versus non-curative comparisons were used in 2 (7.4%) studies. Therapy effectiveness was estimated using a QALY measure in 20 (74.1%) studies, while 7 (25.9%) studies only assessed life-years gained (LYG). A health sector perspective was used in 26 (96.3%) of the evaluations, with only 1 study including costs beyond this perspective. Median intervention cost was $53,954 (range $4550-$4,760,835), with a median incremental cost of $6546 (range - $72,441 to $1,279,764). In cost-utility analyses, 11 (55%) studies found the intervention cost effective using a $100,000/QALY threshold at the time of the study, with an incremental cost-effectiveness ratio (ICER) ranging from - $1,176,091 to $1,152,440 when inflated to 2021 US dollars.

Conclusion: The majority of HCC treatments were found to be cost effective, but with significant variation and with few studies considering indirect costs. Standards for value assessment for HCC treatments may help improve consistency and comparability.

Publication types

Systematic Review